Second-generation highly potent and selective inhibitors of the hepatitis C virus NS3 serine protease.

Abstract

The hepatitis C virus (HCV) infection is a leading cause of chronic liver disease. The moderate efficacy along with side effects of the current pegylated interferon and ribavirin combination therapy underscores the need for more effective and safer new treatment. In an effort to improve upon our current clinical candidate, Boceprevir (SCH 503034), extensive… (More)
DOI: 10.1021/jm801238q

Topics

  • Presentations referencing similar topics